Document Detail


Carboplatin (JM8) as a single agent and in combination in the treatment of small cell lung cancer.
MedLine Citation:
PMID:  3002624     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Carboplatin, a cisplatin analogue without significant nephrotoxicity, was used as a single agent in the treatment of 56 patients with small cell lung carcinoma at a dose of 300-400 mg/m2 i.v. monthly. Twenty-three patients (41%) achieved a response including 5 (9%) complete remissions. Eighteen (60%) of 30 previously untreated patients achieved a response. The drug was well tolerated with nausea or vomiting in only 43% of patients and no nephrotoxicity was seen. Myelosuppression was dose limiting and 39% of patients developed leukopenia. In a subsequent study carboplatin in a dose of 300 mg/m2 was used in combination with etoposide 100 mg/m2 i.v. days 1-3, repeating monthly for 4 courses. So far 32 (89%) of 36 evaluable patients have achieved a response. In patients with limited disease 20/23 patients (87%) have responded including 7 (30%) complete remissions. Leukopenia was dose limiting and occurred in 83% of patients. Carboplatin is a highly active new drug in the treatment of small cell lung cancer.
Authors:
I E Smith; B D Evans
Related Documents :
12597144 - Paclitaxel and carboplatin in neo-adjuvant and concomitant chemoradiotherapy in locally...
25195134 - Psa response rate as a surrogate marker for median overall survival in docetaxel-based ...
9233524 - Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx ...
19409644 - Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcin...
284844 - Combination chemotherapy for acute myelocytic leukemia during pregnancy: three case rep...
22621764 - Acute gastrointestinal and genitourinary toxicity of image-guided intensity modulated r...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Cancer treatment reviews     Volume:  12 Suppl A     ISSN:  0305-7372     ISO Abbreviation:  Cancer Treat. Rev.     Publication Date:  1985 Sep 
Date Detail:
Created Date:  1986-03-07     Completed Date:  1986-03-07     Revised Date:  2006-04-24    
Medline Journal Info:
Nlm Unique ID:  7502030     Medline TA:  Cancer Treat Rev     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  73-5     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Carboplatin
Carcinoma, Small Cell / drug therapy*
Etoposide / administration & dosage
Humans
Lung Neoplasms / drug therapy*
Organoplatinum Compounds / administration & dosage,  adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Organoplatinum Compounds; 33419-42-0/Etoposide; 41575-94-4/Carboplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Carboplatin: the clinical spectrum to date.
Next Document:  Wilms' tumor with intracranial metastases presenting with intracranial hemorrhage.